ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$5.97
-0.50 (-7.69%)
▼
5d:
-8.47%
30d:
+9.7%
90d:
+48.82%
HOLD
LOW Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 05, 2026
15d
Smart Money Accumulation
None View Scanner →
Strength: 8.3/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $5.97, which is considered slightly low relative to its 30-day fair value range of $5.59 to $7.51.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $5.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+62.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $5.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.50 (+62.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.59 -
$7.51
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.7%)
- BULLISH: Trading 62.4% below Wall St target ($10.50)
- CAUTION: Recommendation downgraded due to -8.5% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.59 -
$7.51
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.92
Resistance Level
$8.44
Current Trend
Strong Uptrend
Technical data as of
Jul 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.17
Wall Street Target
$10.50
(+62.4%)
Revenue Growth (YoY)
96.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-181.7%
Share & Embed Analysis
Last updated: July 20, 2026 2:12 PM ET
Data refreshes hourly during market hours. Next update: 3:12 PM
Data refreshes hourly during market hours. Next update: 3:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$435 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$301 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
